Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Wed., Jun. 29, 8:19 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #90 of 100 |
Slide #90. Imprimis Pharmaceuticals, Inc. — Intellectual Property Assets from Buderer Drug Company
Acquirer:
Imprimis Pharmaceuticals, Inc. (IMMY)
Acquiree:
Intellectual Property Assets from Buderer Drug Company
Details:
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company. The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and also provides Imprimis with a right of first refusal on additional Buderer Drug Company intellectual property and drug development opportunities.
Imprimis Pharmaceuticals is an ophthalmology-focused pharmaceutical company focused on the development, production and sale of medications. Co. operates its business through several subsidiaries: ImprimisRx, an ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient specific orders; and Surface Pharmaceuticals, Inc., an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary.
Open the IMMY Page at The Online Investor »
|
|||||||||
Open the IMMY Page at The Online Investor (in a new window) »
 Free IMMY Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
